It operates in the world of health and science. It has 24,090 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (3% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $3.1B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 18 buys and 6 sells. Management buying with its own money is usually read as a good sign.
A loss of $262.7M against $3.1B in annual sales.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, BKDTU sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BKDTU has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.